On December 3, 2020 Veracyte, Inc. (Nasdaq: VCYT), a global genomic diagnostics company, reported that it will host a Virtual Lung Cancer R&D Day for investors and analysts on December 16, 2020, from 10:00 a.m. to 12:00 p.m. EST (Press release, Veracyte, DEC 3, 2020, View Source [SID1234572126]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature Veracyte senior management who will provide an overview of the company’s vision for transforming patient care in lung cancer, as well as leading pulmonologists who will discuss the challenges and opportunities in lung cancer diagnosis and treatment. Veracyte will also provide updates on its lung cancer product pipeline, including its Nasal Swab Test, for early diagnosis of lung cancer, and Percepta Atlas, for informing treatment decisions at the time of diagnosis. The company plans to launch both products in the second half of 2021.

A link to register for the event is available here and can also be accessed through Veracyte’s website at View Source A replay of the presentation will be available on the company’s website for approximately 90 days.